Development of treatment in pseudomyxoma peritonei: using genome analysis and high-throughput drug screening of patient-derived model

2020 Fiscal Year Final Research Report

• Project/Area Number: 19K18136
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55020:Digestive surgery-related
• Research Institution: National Cancer Center Japan
• Principal Investigator: Noguchi Rei 国立研究開発法人国立がん研究センター, 研究所, 特任研究員 (30779682)
• Project Period (FY): 2019-04-01 – 2021-03-31
• Keywords: 腹膜偽粘液腫 / 患者由来がんモデル / セルソーター / 無血清培地

Outline of Final Research Achievements

Pseudomyxoma peritonei (PMP) is a rare tumor with an estimated incidence of 1-2 per million per year. PMP shows a variety of clinical manifestations by the dissemination of mucin producing tumor cells in peritoneal cavity. The current standard therapy for PMP is complete cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC), which improved the prognosis of patients with PMP. However, 30-40% of patients were not treated by HIPEC by their advanced disease, and patients with recurrent disease are difficult to cure. Novel therapies are required to treat PMP. Although patient-derived cell lines are a critical tool for basic and pre-clinical research, only one PMP cell line is reportedly available for analysis. Thus, we aimed to establish and characterize a novel patient-derived cell line for PMP. Using tumor tissue of a patient with PMP, we established two PMP cell lines and identified effective anti-cancer drugs using the established PMP cell lines.

Free Research Field

希少がん

Academic Significance and Societal Importance of the Research Achievements

100万人に1人の割合で発症する希少がんである腹膜偽粘液腫は研究に用いることのできるモデル生物がない。そのため、治療法開発が進まず、既存の治療法で治療を行っている。本研究で腹膜偽粘液腫のの患者由来がんモデルを作製し、それを用いて、薬剤標的および薬剤を同定することで、腹膜偽粘液腫の治療に前臨床段階にて貢献することができる。